Business
OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
Type C Meeting with US FDA set for December 11, 2025 to address key items following August 27, 2025 End of Phase 2 Meeting regarding Phase 2b clinical trial of OST-HER2: prevention or delay of recurrent, fully-resected pulmonary metastatic osteosarcomaUS Biologics Licensing Application (BLA) and UK MHRA Marketing Authorization Application filings for OST-HER2 expected in January 2025 leveraging Project OrbisUK MHRA pre-Marketing Authorization Application (MAA) meeting scheduled for December 8,..
About this update from Os Therapies Incorporated
[{"type":"list","items":[{"val":[{"type":"text","content":"Type C Meeting with US FDA set for December 11, 2025 to address key items following August 27, 2025 End of Phase 2 Meeting regarding Phase 2b clinical trial of OST-HER2: prevention or delay of recurrent, fully-resected pulmonary metastatic osteosarcoma","length":252,"tagName":"p"}]},{"val":[{"type":"text","content":"US Biologics Licensing Application (BLA) and UK MHRA Marketing Authorization Application filings for OST-HER2 expected in January 2025 leveraging Project Orbis","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"UK MHRA pre-Marketing Authorization Application (MAA) meeting scheduled for December 8, 2025; EMA pre-MAA meeting request now granted, awaiting scheduling","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"$7.8 million warrant exercise inducement allowed for key one-time regulatory-related payments and provided Company with capital into late 2026 by delaying launch to 2027","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"Company remains eligible to receive Priority Review Voucher (PRV) based on Pediatric Rare Pediatric Disease Designation (RPDD) for Osteosarcoma if approved by September 30, 2026","length":177,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":911,"olType":false},{"type":"text","content":"New York, New York--(Newsfile Corp. - November 17, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today reported third quarter 2025 financial results for the period ended September 30, 2025 and provided a business update.","length":336,"tagName":"p"},{"type":"text","content":""The next six to twelve months will be transformative for OS Therapies," said Paul Romness, MPH, Chairman & CEO of OS Therapies. "OST-HER2's recently reported strong 2-year overall survival data that allows the Company to align our regulatory strategy with FDA Draft Guidance August 18, 2025 'Approaches to Assessment of Overall Survival in Oncology Clinical Trials' for Industry. The Company expects to align on the expectations for our pending BLA for OST-HER2 under the Accelerated Approval Program at our December 11, 2025 FDA Type C Meeting. We expect to file the BLA in January 2026."","length":626,"tagNam...